publication date: Dec. 20, 2010

In this issue: 

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.

Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.

Richard Bloch, advocate for patient information services, dead at 78.

STAR completes enrollment.

NCI forms pediatric central IRB.

Funding opportunities listed.

July issue of Business & Regulatory report (8 additional pages) included.

Download (PDF 161KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.